REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
41.75 USD
4.41 B USD
14.20 B USD
102.13 M
About Regeneron Pharmaceuticals, Inc.
Sector
Industry
CEO
Leonard S. Schleifer
Website
Headquarters
Tarrytown
Founded
1988
ISIN
US75886F1075
FIGI
BBG000C734W3
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
—
Maturity date
Sep 15, 2030
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
—
Maturity date
Sep 15, 2050
See all REGN bonds
Curated watchlists where REGN is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Regeneron Pharmaceuticals, Inc. stocks are traded under the ticker REGN.
We've gathered analysts' opinions on Regeneron Pharmaceuticals, Inc. future price: according to them, REGN price has a max estimate of 890.00 USD and a min estimate of 543.00 USD. Watch REGN chart and read a more detailed Regeneron Pharmaceuticals, Inc. stock forecast: see what analysts think of Regeneron Pharmaceuticals, Inc. and suggest that you do with its stocks.
REGN reached its all-time high on Aug 20, 2024 with the price of 1,198.87 USD, and its all-time low was 482.02 USD and was reached on Jun 6, 2025. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Regeneron Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Regeneron Pharmaceuticals, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 12.89 USD per share, whereas the estimation was 8.43 USD resulting in a 52.89% surprise. The estimated earnings for the next quarter are 9.65 USD per share. See more details about Regeneron Pharmaceuticals, Inc. earnings.
Regeneron Pharmaceuticals, Inc. revenue for the last quarter amounts to 3.68 B USD, despite the estimated figure of 3.29 B USD. In the next quarter, revenue is expected to reach 3.57 B USD.
REGN net income for the last quarter is 1.39 B USD, while the quarter before that showed 808.70 M USD of net income which accounts for 72.08% change. Track more Regeneron Pharmaceuticals, Inc. financial stats to get the full picture.
Yes, REGN dividends are paid quarterly. The last dividend per share was 0.88 USD. As of today, Dividend Yield (TTM)% is 0.46%. Tracking Regeneron Pharmaceuticals, Inc. dividends might help you take more informed decisions.
Regeneron Pharmaceuticals, Inc. dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 12, 2025, the company has 15.11 K employees. See our rating of the largest employees — is Regeneron Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regeneron Pharmaceuticals, Inc. EBITDA is 4.47 B USD, and current EBITDA margin is 32.79%. See more stats in Regeneron Pharmaceuticals, Inc. financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regeneron Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.